Children's Hospital and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Eur J Endocrinol. 2020 Nov;183(5):513-520. doi: 10.1530/EJE-20-0516.
To determine the natural course of pubertal development, growth during puberty, and development of POI in females with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also called autoimmune polyendocrine syndrome type I.
Longitudinal follow-up study.
A national cohort of females with APECED aged ≥12 years were followed during 1965-2018. Attainment of adult height was defined when patients' height increased less than 1 cm per year. Diagnosis of POI was based on delayed puberty or POI symptoms with amenorrhea, and/or FSH ≥40 IU/L.
Altogether 40 women with APECED were followed up to the average age of 37.3 (range: 14.6-61.9) years; 16 females (40%) were ≥ 40 years. Pubertal development started spontaneously in 34 patients and 29 had spontaneous menarche. POI developed in 28 patients (70%) at the median age of 16.0 years (range: 11.3-36.5), and in 20 of them (71%) before attaining adult height. In 11 cases puberty was induced or completed by hormonal therapy. Patients with POI were significantly shorter at menarche, but adult heights did not differ from non-POI females. Patients with POI had more often primary adrenocortical insufficiency (93% vs 58%, P = 0.017) and ovarian antibodies (81% vs 30%, P=0.003) compared to those with normal ovarian function (n = 12).
POI developed in the majority of patients with APECED, often before or shortly after menarche. Timely commencement of hormonal replacement therapy is important to ensure optimal pubertal development and growth. The possibility of fertility preservation before development of POI in APECED patients should be further studied.
确定自身免疫性多内分泌腺病-念珠菌病-外胚层发育不良(APECED)女性的青春期发育、生长和原发性卵巢功能不全(POI)的自然病程,也称为自身免疫性多内分泌腺病综合征 1 型。
纵向随访研究。
对 1965 年至 2018 年期间年龄≥12 岁的 APECED 女性进行全国性队列研究。当患者身高每年增加少于 1 厘米时,定义为达到成人身高。POI 的诊断基于青春期延迟或 POI 症状伴闭经和/或 FSH≥40 IU/L。
共对 40 名 APECED 女性进行了随访,平均年龄为 37.3 岁(范围:14.6-61.9);16 名女性(40%)≥40 岁。34 名患者自发性开始青春期发育,29 名患者自发性初潮。28 名患者(70%)在 16.0 岁的中位数年龄(范围:11.3-36.5)发生 POI,其中 20 名(71%)在达到成人身高之前发生。11 例通过激素治疗诱导或完成青春期。POI 患者的初潮时身高明显较矮,但成年身高与非 POI 女性无差异。POI 患者更常发生原发性肾上腺皮质功能不全(93%比 58%,P=0.017)和卵巢抗体(81%比 30%,P=0.003),而卵巢功能正常的患者(n=12)较少见。
APECED 患者中,POI 多发生在青春期初潮前或初潮后不久。及时开始激素替代治疗对确保青春期正常发育和生长非常重要。应进一步研究在 APECED 患者发生 POI 之前进行生育力保存的可能性。